Clinical trials: Environmental Exposures
Dry Eye Disease
A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
A Multicenter, Phase 3, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Environment Exposure Clinical Trial to Assess the Efficacy and Safety of 0.25% Reproxalap
- Trial name
- NCT06424444
- Testing
- Reproxalap ophthalmic solution (0.25%), Vehicle ophthalmic solution
- Where
- United States
- Volunteers
- 421 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Allergic Conjunctivitis
The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
The INVIGORATE Trial: A Randomized, Double-masked, Crossover Design, Phase 3 Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.
- Trial name
- NCT04207736
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 95 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Healthy Adult Participants
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
The goal of this observational study is to evaluate the feasibility and usability of at-home urine sample collection, preparation, and smartphone imaging using the EcoExposure™ platform in adults.
- Trial name
- OMNU (NCT07775495)
- Where
- 51 sites in United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Ecotera Health LLC
Cat Allergy, Rhinoconjunctivitis
An Optional Two Year Follow Up Study to Study CP005A
Cat allergy is an increasingly prevalent condition affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT01604018
- Where
- Canada
- Volunteers
- 51 people
- Sponsor
- Circassia Limited
Asthma
A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma
This was a 3-center, randomized, double-blind, parallel-group, placebo-controlled study with a 16-week treatment phase to determine whether subcutaneous omalizumab, compared with placebo, reduces the degree of bronchoconstriction…
- Trial name
- AERO (NCT00495612)
- Testing
- Omalizumab
- Volunteers
- 69 people
- Sponsor
- Genentech, Inc.
Seasonal Allergic Rhinitis
Compare Captisol-Enabled (CE) Budesonide + Azelastine Nasal Solution and Rhinocort Aqua + Astelin in an Environmental Exposure Chamber (EEC) Study of Allergic Rhinitis
The primary objective of this study was to compare Placebo to Captisol-Enabled Budesonide + Azelastine in a single spray and two separate sprays (Budesonide + Azelastine) in patients with Seasonal Allergic Rhinitis exposed to…
- Trial name
- NCT00940953
- Testing
- Budesonide + Azelastine
- Where
- Canada
- Volunteers
- 108 people
- Sponsor
- Ligand Pharmaceuticals
Seasonal Allergic Rhinitis
Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber
The purpose of this study is to determine whether Ragweed-SPIRE is safe and effective at reducing allergy symptoms in people who suffer from allergy to Ragweed pollen
- Trial name
- NCT02061709
- Testing
- Ragweed-SPIRE
- Where
- 5 sites in Canada
- Volunteers
- 280 people
- Sponsor
- Circassia Limited
Cat Allergy
Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects
Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma.
- Trial name
- NCT00729508
- Testing
- Cat-PAD
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Circassia Limited
Lead Poisoning, Environmental Exposure
A Study to Assess the Efficacy of Public Health Campaigns in Reducing Lead Exposure
This clinical trial aims to evaluate the effectiveness of targeted public health campaigns in reducing lead exposure among adults living in urban communities with known environmental lead hazards.
- Trial name
- NCT07632937
- Testing
- Intensive Public Health Campaign, Standard Information Dissemination
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- International Health Strategies LLC
Allergic Conjunctivitis
The INVIGORATE 2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis
The INVIGORATE 2 Trial: A single-center, randomized, double-masked, crossover design, vehicle-controlled, Phase 3 clinical trial to assess the efficacy and safety of reproxalap ophthalmic solution (0.25%) compared to vehicle in…
- Trial name
- NCT05234554
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 131 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Seasonal Allergic Rhinitis
Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)
A single-center, double-blind, placebo-controlled study of FDC olopatadine hydrochloride and mometasone furoate nasal spray (Molo; also referred as GSP 301) was conducted in subjects with seasonal allergic rhinitis.
- Trial name
- GSP 301- PoC (NCT03444506)
- Testing
- Molo 1 (also referred as GSP 301-2 NS), Molo 2 (also referred as GSP 301-1 NS), DYMISTA nasal spray
- Where
- Canada
- Volunteers
- 180 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Seasonal Allergic Rhinitis
Azelastine Allergen Chamber - Onset of Action Study
This study is to assess the Onset of Action and Efficacy of azelastine hydrochloride 0.15% in treating the nasal symptoms of seasonal allergic rhinitis (SAR) induced by an allergen challenge in an Environmental Exposure Unit…
- Trial name
- NCT06126952
- Testing
- Treatment A: Azelastine hydrochloride 0.15% nasal spray (Azelair), Treatment C: Ryaltris (Active Control) - mometasone furoate monohydrate and olopatadine hydrochloride nasal spray
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Allergic Conjunctivitis
A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)
This is a Phase II Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel, Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis…
- Trial name
- NCT02082899
- Testing
- Active Comparator EBI-005 5 mg/mL
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Eleven Biotherapeutics
Allergic Rhinoconjunctivitis
A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber
This trial evaluates the efficacy and safety of HDM SLIT-tablet in treatment of HDM AR. The efficacy is evaluated using an environmental exposure chamber (EEC).
- Trial name
- QUEST (NCT04176185)
- Testing
- Sublingual allergy immunological tablet
- Where
- 2 sites in Austria, China
- Volunteers
- 80 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis
An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis
The purpose of this study is to evaluate the relative efficacy of JNJ- 39220675 and pseudoephedrine compared to placebo (medication with no active ingredients) in participants with allergic rhinitis (inflammation of the nose due…
- Trial name
- NCT00804687
- Testing
- JNJ-39220675, Pseudoephedrine
- Where
- Canada
- Volunteers
- 53 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Rhinitis, Allergic, Seasonal
Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects
To compare the clinical efficacy of levocetirizine 5 mg and montelukast 10 mg on symptoms of seasonal allergic rhinitis occurring in subjects exposed to ragweed pollen in an environmental exposure unit.
- Trial name
- NCT00295022
- Testing
- Montelukast, Levocetirizine
- Where
- Canada
- Volunteers
- 418 people
- Sponsor
- UCB S.A. - Pharma Sector
Pulmonary Disease, Chronic Obstructive
Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug
This single and repeat increasing dose study will collect information on safety, tolerability and drug levels in the body of the CCI15106 inhalation powder.
- Trial name
- NCT03235726
- Testing
- CCI15106
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rhinitis, Allergic
A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure
The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering…
- Trial name
- NCT03443843
- Testing
- loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D), Fluticasone Propionate
- Where
- Canada
- Volunteers
- 82 people
- Sponsor
- Bayer
Endocrine Disrupting Chemicals, Environmental Exposure
Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age
The goal of this intervention study is to determine to what extent the Million Marker (MM) program reduces users' endocrine disruption chemical (EDC) exposure levels and changes their environmental health awareness and behaviors.
- Conditions
- Endocrine Disrupting Chemicals, Environmental Exposure, Health Literacy, Bisphenol A
- Trial name
- NCT05780047
- Testing
- Mail-in Urine Test for EDCs
- Where
- United States
- Volunteers
- 434 people, healthy volunteers welcome
- Sponsor
- Million Marker Wellness, Inc.
Seasonal Allergic Rhinitis
Effect of Loratadine/Montelukast Combination on Congestion in SAR Patients Exposed to Pollen in an EEU (Study P04822)
This is study of LMC, phenylephrine, and placebo in subjects with SAR. There are three visits: At Visit 1, subjects will be evaluated for participation and, if they qualify, will attend Visit 2 for priming.
- Trial name
- NCT00423995
- Testing
- Loratadine/montelukast combination
- Volunteers
- 379 people
- Sponsor
- Organon and Co